Core Viewpoint - The approval of PegBio's GLP-1RA drug, Weipinaitai (派达康®), for the treatment of type 2 diabetes (T2DM) by the National Medical Products Administration of China has led to a significant increase in the company's stock price, reflecting positive market sentiment and potential growth in the diabetes treatment sector [1] Company Summary - PegBio's stock surged over 12%, reaching HKD 63.5, with a trading volume of HKD 28.2 million following the drug approval announcement [1] - The company's GLP-1RA drug is expected to capture a significant share of the growing diabetes treatment market in China [1] Industry Summary - The global T2DM drug market has experienced a compound annual growth rate (CAGR) of approximately 29.3% from 2018 to 2023 [1] - The market share of GLP-1 receptor agonists has increased from about 8.4% in 2018 to approximately 29.3% in 2023 [1] - Long-acting GLP-1 receptor agonists are projected to dominate the Chinese market, expected to account for over 80% of the market share by 2032 [1]
港股异动 | 派格生物医药-B(02565)尾盘涨超12% 核心产品维培那肽注射液获批上市